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Distinct Functions for Anterograde and Retrograde Sorting
of SORLA in Amyloidogenic Processes in the Brain
Sonya B. Dumanis,1* Tilman Burgert,1* Safak Caglayan,1 Annette Fu¨chtbauer,2 Ernst-Martin Fu¨chtbauer,2
Vanessa Schmidt,1 and Thomas E. Willnow1
1Max Delbrueck Center for Molecular Medicine, D-13125 Berlin, Germany and 2Department of Molecular Biology and Genetics, Aarhus University,
DK-8000 Aarhus, Denmark
SORLA is a neuronal sorting receptor implicated both in sporadic and familial forms ofAD. SORLA reduces the amyloidogenic burdenby
two mechanisms, either by rerouting internalized APPmolecules from endosomes to the trans-Golgi network (TGN) to prevent proteo-
lytic processing or by directing newly produced A to lysosomes for catabolism. Studies in cell lines suggested that the interaction of
SORLA with cytosolic adaptors retromer and GGA is required for receptor sorting to and from the TGN. However, the relevance of
anterogradeor retrograde trafficking for SORLAactivity in vivo remained largely unexplored.Here,we generatedmousemodels express-
ing SORLA variants lacking binding sites for GGAor retromer to query this concept in the brain. Disruption of retromer binding resulted
in a retrograde-sorting defect with accumulation of SORLA in endosomes and depletion from the TGN, and in an overall enhanced APP
processing. In contrast, disruption of the GGA interaction did not impact APP processing but caused increased brain A levels, a
mechanism attributed to a defect in anterograde lysosomal targeting of A. Our findings substantiated the significance of adaptor-
mediated sorting for SORLA activities in vivo, and they uncovered that anterograde and retrograde sorting paths may serve discrete
receptor functions in amyloidogenic processes.
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Introduction
Sorting protein-related receptor with A-type repeats (SORLA)
is a member of the vacuolar protein sorting 10 protein
(VPS10P) gene family, a group of neuronal sorting receptors
that traffic target proteins between Golgi, plasma membrane,
and endosomes. Earlier work identified central roles for
VPS10P domain receptors in control of neuronal viability and
function, and in the occurrence of neurodegenerative diseases
(for review, see Willnow et al., 2008).
Concerning SORLA, association studies link variants of SORL1
(the gene encoding SORLA) with increased risk of sporadic AD (Ro-
gaeva et al., 2007; Naj et al., 2011). Additionally, recent findings
suggest that SORL1 mutations may also underlie autosomal domi-
nant familial forms of this disease (Pottier et al., 2012). According to
current models, SORLA impacts AD-related processes by two dis-
tinct mechanisms. It acts as a trafficking receptor for APP, which
redirects APP from endosomes to the trans-Golgi network (TGN),
reducing the extent of proteolytic breakdown into amyloidogenic
and nonamyloidogenic products (Offe et al., 2006; Schmidt et al.,
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Significance Statement
SORLA is a sorting receptor that directs target proteins to distinct intracellular compartments in neurons. SORLA has been
identified as agenetic risk factor for sporadic, but recently also for familial formsofAD.Toconfirm the relevanceof SORLAsorting
for AD processes in the brain, we generated mouse lines, which express trafficking mutants instead of the wild-type form of this
receptor. Studying neuronal activities in these mutant mice, we dissected distinct trafficking routes for SORLA guided by two
cytosolic adaptors termed GGA and retromer. We show that these sorting pathways serve discrete functions in control of amy-
loidogenic processes and may represent unique therapeutic targets to interfere with specific aspects of neurodegenerative pro-
cesses in the diseased brain.
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2007). SORLA also acts as a sorting factor for A, moving newly
produced peptides to lysosomes for catabolism, further reducing the
amyloidogenic burden (Caglayan et al., 2014).
Given the importance of SORLA-mediated protein sorting in
AD, major attention has been focused on mechanisms governing
receptor trafficking at the TGN. Two adaptors received particular
attention, the Golgi-localizing, -adaptin ear homology domain
ARF-interaction proteins (GGAs) and the retromer complex,
both of which bind to the cytoplasmic tail of SORLA and are also
genetically linked to AD (Small and Gandy, 2006; Wahle et al.,
2006; Muhammad et al., 2008). Retromer is a pentameric adaptor
complex involved in retrograde sorting of proteins from early
endosomes to the TGN (Seaman, 2004; Small, 2008; Fjorback et
al., 2012). GGAs mediate anterograde transport of cargo from the
TGN to endosomes (Jacobsen et al., 2002; Herskowitz et al.,
2012). In established cell lines, disruption of retromer or GGA
binding to SORLA impairs trafficking of the receptor and alters
APP processing fates (Schmidt et al., 2007; Herskowitz et al.,
2012). However, direct proof that these sorting pathways are re-
quired for SORLA activity in vivo is lacking.
Here we generated mouse models expressing SORLA mutants
defective in binding to retromer or GGAs, and we show that
Figure 1. Mice expressing human SORLA variants. A, Constructs encoding wild-type SORLA (SORLAWT) or receptor variants lacking the GGA (SORLA GGA) or retromer binding (SORLA FTAF) motifs
for targeting themurine Rosa26 locus are shown. Amino acid sequences of the cytoplasmic domains of the receptor variantswith residuesmodified bymutagenesis in the GGA (green) and retromer
(red) binding mutants are indicated. The scheme for introducing the targeting vectors between exons 1 and 2 (black squares) of Rosa26 is given below. Removal of the loxP-flanked neomycin
resistance cassette (neoR) enables transcription of the SORLA cDNAs from the Rosa26 promoter (activated Rosa26 locus). B, Immunodetection of SORLA (green) in cortices of mice of the indicated
genotypes. Sectionswere costained for theneuronalmarkerNeuN (blue; left) or astroglialmarker GFAP (red) andDAPI (white; right). No immunoreactivity for SORLA is detectable in Sorl1/ tissue
(used as negative control). Scale bar, 10m. C, DWestern blot analysis (C) and quantification by densitometric scanning of replicate blots (D) documents increased levels for SORLA GGA compared
with SORLAWT and SORLA FTAF in brain extracts (n 3 animals/genotype; *p 0.05, **p 0.01, one-way ANOVA, Tukey post hoc analysis). Detection of Na/K ATPase (Na/K) served as loading
control in C.
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disrupting these trafficking pathways differentially impacts
SORLA activities in vivo. Lack of retromer binding impairs the
APP sorting function of SORLA, resulting in an accumulation of
the receptor in endosomes and in increased APP processing. In
contrast, disrupting GGA binding decreases SORLA-dependent
lysosomal targeting of A, causing accumulation of the peptide
in the brain. Our data document that SORLA-dependent traffick-
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retrograde sorting, and that these pathways depend on the recep-
tor interaction with GGAs and retromer, respectively.
Materials andMethods
Generation of mouse models. The generation of mice carrying a
cDNA encoding wild-type human SORLA in the Rosa26 locus
(Rosa26TgSORLAwt) has been described (Burgert et al., 2013). The same
strategy was applied to generate mice carrying constructs for SORLA
variants lacking GGA (Rosa26TgSORLAgga) or retromer binding sites
(Rosa26TgSORLftaf; Fig. 1A). The constructs were introduced into the mu-
rine Rosa26 gene locus using homologous recombination. Mice carrying
the transgenes through their germline were crossed with the Cre deleter
strain (Taconic) to remove a triple transcription stop site and to enable
expression from the endogenous Rosa26 promoter.
Analysis of brain tissue. Characterization of cortical brain tissues by
fluorescence microscopy or Western blotting was performed using stan-
dard protocols. APP processing products were determined by multiplex
assays (Meso Scale Discovery). Analyses were performed in female mice
at 8 –10 weeks of age. For differential extraction of A, brain cortices
were dissected and homogenized in ice-cold homogenization buffer
(0.25 mM sucrose, 2 mM MgCl2, and 20 mM Tris-HCl, pH 7.5). Following
incubation for 20 min on ice, nuclei and cellular debris were removed by
a centrifugation step (1000  g, 10 min). The lysate was centrifuged
(100,000  g, 1 h), with the lysate becoming the soluble fraction. The
pellet was resuspended in lysis buffer (1% NP-40, 1% Triton X-100, 50
mM Tris-HCl, pH 7.4, 300 mM NaCl) and centrifuged (100,000 g, 1 h),
with the new lysate labeled as the membrane bound fraction. This frac-
tion was used for Western blot analysis. The pellet was subsequently
resuspended in 70% formic acid, vortexed for 2 h, and centrifuged at
100,000 g for 1 h. The resulting supernatant was neutralized in 1 M Tris
and labeled the formic acid soluble fraction. All buffers were supple-
mented with protease inhibitor (05 892 791 001; Roche) and phosphatase
inhibitors (78440; Thermo Scientific).
Hippocampal cell cultures. Primary neurons were generated from P1
mice and analyzed at 5 DIV (Rohe et al., 2008). Pearson’s coefficient was
determined using Fiji/ImageJ software. At least 20 neurons were imaged
per condition. Experiments were replicated at least three times. Stud-
ies comparing SORLA GGA with SORLA WT and SORLA FTAF with
SORLA WT strains were performed separately, therefore, statistically sig-
nificant differences between mutant and wild-type lines in each group
were evaluated using Student’s t test. There was no statistically significant
difference in the Pearson’s coefficients of the respective SORLA WT con-
dition in both group sets.
Analysis of SH-SY5Y cells. For pulse chase experiments, SH-SY5Y cells
stably overexpressing SORLA WT, SORLA GGA, or SORLA FTAF were in-
cubated in methionine-free medium for 60 min before adding 1.5 mM of
the methionine analog L-azidohomoalanine (AHA; Invitrogen). After a
30 min pulse, the cells were chased for various time points and lysed.
Using Click-It chemistry, an alkyne-biotin tag was added to AHA in the
labeled proteins. Lysates were precipitated with protein A-Sepharose
precoated with anti-SORLA IgG, and precipitates were subjected to SDS-
PAGE and immunodetection with Streptavidin-HRP. Following densi-
tometric scanning of replicate blots (n  8 per condition), values were
normalized to time point 0 of each experiment (set to 100%). A best-fit,
one-phase exponential decay curve (y  Span eKx  Plateau) was
determined using GraphPad Prism software, with t1⁄2  0.6932/K. For
the DAPT experiments, 5 M DAPT [in the absence or presence of a
lysosomal inhibitor cocktail (100 M leupeptin, 10 M pepstatin A, and
50 M chloroquine)] was added to SH-SY5Y cells stably overexpressing
APP and SORLA WT, or APP and SORLA GGA (n  9 replicates). The
decay of intracellular A was determined as published previously
(Caglayan et al., 2014).
Figure 3. SORLA levels in primary neurons expressing wild-type and mutant receptor variants. A, Representative images for primary hippocampal neurons (DIV 5) of the indicated genotypes
stained for SORLA (green) and DAPI (blue; top), or for neuronal marker MAP2 (white) and DAPI (blue; bottom). Analysis of neuronal cultures from Sorl1/mice served as negative control. Scale
bar, 10m. B, C, Levels of SORLA variants were tested by Western blotting of total cell lysates of primary neurons (B) and quantification by densitometric scanning of replicate blots (C). Levels of
SORLA GGA were increased compared with SORLAWT and SORLA FTAF (n 4 per genotype; *p 0.05, one-way ANOVA, Tukey post hoc analysis).
12706 • J. Neurosci., September 16, 2015 • 35(37):12703–12713 Dumanis, Burgert et al. • Retromer- versus GGA-Dependent Transport of SORLA In Vivo
Results
To query the relevance of adaptors for SORLA trafficking in vivo,
we generated two mouse models that express receptor variants de-
fective in binding to GGA (SORLAGGA) or retromer (SORLAFTAF).
We have applied this strategy before to produce mice expressing
wild-type human SORLA (Burgert et al., 2013). In brief, we used
PCR-based mutagenesis of the human SORLA cDNA to replace
binding site residues for GGA (2207DDVPMV2212) or retromer
(2169FTAF2172) in the cytoplasmic receptor domain by alanine resi-
dues (Fig. 1A). These modifications eliminate the ability of SORLA
to interact with these adaptors in cultured cells (Schmidt et al., 2007;
Fjorback et al., 2012). The cDNA constructs were introduced into
theRosa26 locus of mice and activated by Cre-mediated recombina-
tion using the Cre deleter strain (Fig. 1A). Mice carrying the activated
SORLA transgenes were crossed with animals having a targeted dis-
ruption of the endogenous SORLA locus (Sorl1/; Andersen et al.,
2005) to eliminate expression of the endogenous murine receptor.
The corresponding mouse lines (Rosa26TgSORLAgga, Sorl1/)
and (Rosa26TgSORLAftaf, Sorl1/) are referred to as SORLA GGA
and SORLA FTAF, respectively. They were compared
with(Rosa26TgSORLAwt, Sorl1/) animals (SORLA WT) ex-
pressing the human wild-type receptor in Rosa26.
Using immunohistology, we showed that all SORLA variants
localized predominantly in the perinuclear region of neurons in
the brain, similar to the pattern seen for the murine receptor in
Sorl1/mice. No coexpression of the endogenous receptor or of
transgenic SORLA variants with GFAP, a marker for astrocytes,
was observed (Fig. 1B). This restricted expression of SORLA
transgenes from Rosa26 has been seen before and argued for cel-
lular mechanisms that enable expression of this receptor in neu-
rons but not in glia in vivo (Burgert et al., 2013; Caglayan et al.,
2014). Surprisingly, SORLA GGA mice showed a stronger SORLA
immunoreactivity compared with SORLA WT and SORLA FTAF
(Fig. 1B). This notion was confirmed by Western blotting docu-
Figure 4. Aberrant trafficking of SORLA GGA and SORLA FTAF in hippocampal neurons. A–C, Primary hippocampal neurons of the indicated genotypes stained for SORLA (green), DAPI (blue), and
either VTi1b (red;A), Rab5 (red;B), or Lamp1 (red; C). Pearson’s coefficients are given in themerged parts. High-magnification insets indicate colocalization of SORLAwith the respectivemarker. At
least 20 neurons per genotype were imaged [*p 0.05;**p 0.01; ***p 0.001; Student’s t test (as SORLAWT and SORLA GGA were performed separately from SORLAWT and SORLA FTAF
experiments].D,Model of howSORLA localization changes inmutant receptor variants. SORLAWT is foundpredominantly in the TGN,but also in endosomesand lysosomes (top). Anterograde sorting
from TGN to the endosomal/lysosomal compartments is mediated by GGAs (green arrow). Loss of this interaction results in SORLA GGA accumulation in the TGN and depletion from lysosomes
(middle). Retrograde sorting of SORLAWT is mediated by retromer (red arrow). Loss of this interaction causes accumulation of SORLA FTAF in early endosomes but depletion from the TGN (bottom).
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Figure 5. SORLA GGA and SORLA FTAF differentially impact amyloidogenic processing. SORLAWT, SORLA GGA, and SORLA FTAF mice were crossed with the 5xFAD line. Cortical lysates were collected
from females at 8–10weeks of age and analyzed as indicated. A–D, Quantification by ELISA documents no changes in sAPP and sAPP (swAPP). (A), but an increase in A40 and A42 levels
(B) in SORLA GGA comparedwith SORLAWTmice in the soluble brain fraction (n 12 animals/group). No difference in A40 and A42 levelswas seenwhen themembrane bound (C) or formic acid
soluble fractions (D)were analyzed (n 6–7 animals/group). E–H, ELISA documents increases in sAPP and sAPP (E) and in A40 andA42 (F ) in SORLA FTAF comparedwith SORLAWT animals
(n 14–15 animals/group) in the cytosolic brain fraction. Parallel experiments to E and F were performed, and quantification by ELISA documented no changes in A40 and A42 levels in
SORLA FTAF comparedwith SORLAWT animals in themembranebound (G) or formic acid soluble (H ) fractions (n7animals/group). Statistical analyseswereperformedusing Student’s t test (*p
0.05; **p 0.01; ***p 0.001).
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menting 56% increased levels of SORLA GGA compared with the
other receptor variants (Fig. 1C,D). Expression of the human
SORLA variants did not alter brain levels (Fig. 2A,B) or cellular
localization (Fig. 2C) of retromer subunits VPS26 and VPS35, of
GGA1, GGA2, or GGA3, or of other SORLA adaptors, including
PACS1, AP2 (-subunit), or AP1 (-adaptin; Fig. 2A,B). Also,
the SORLA binding partners APP and cation-independent
mannose-6 phosphate receptor (CI-MPR) showed comparable
brain expression patterns in all genotypes (Fig. 2).
Next, we asked whether disruption of adaptor binding alters
SORLA sorting in neurons as suggested by experiments in non-
neuronal cell lines (Nielsen et al., 2007; Schmidt et al., 2007;
Herskowitz et al., 2012). Consistent with our observation in vivo
(Fig. 1B), all three SORLA variants localized to the perinuclear
region in primary hippocampal neurons with expression of
SORLA GGA being increased compared with SORLA WT and
SORLA FTAF. This increase was seen by immunocytochemistry
(Fig. 3A) and by Western blotting (Fig. 3B,C). To test for neuro-
nal protein sorting, we costained primary neurons from the var-
ious mouse lines for SORLA and the organelle markers Vti1b
(TGN; Fig. 4A), Rab5 (early endosomes; Fig. 4B), or Lamp1
(lysosomes; Fig. 4C). Colocalization of SORLA with these mark-
ers was determined by the Pearson’s coefficient. Consistent with
the established pattern of endogenous SORLA, SORLA WT local-
ized mainly to the TGN, and to a lesser extent to early endosomes
and lysosomes. In contrast, SORLA GGA showed increased local-
ization to the TGN and to early endosomes, but a loss from lyso-
somes. Immunosignals for SORLA FTAF were increased in
endosomes, but decreased in the TGN. Localization to lysosomes
in SORLA FTAF was not changed compared with SORLA WT.
These data confirmed the relevance of GGA and retromer inter-
actions for SORLA sorting in neurons. Specifically, they sug-
gested that loss of anterograde sorting in SORLA GGA retains
retrograde trafficking from early endosomes back to the TGN,
bypassing lysosomal receptor targeting (Fig. 4D). In contrast, loss
of retrograde sorting in SORLA FTAF promotes the anterograde
movement of receptors to endosomal compartments, depleting it
from the TGN (Fig. 4D).
Having confirmed the necessity of retromer and GGA inter-
actions for receptor sorting, we tested whether loss of these inter-
actions impacts the activities of SORLA in amyloidogenic
processes. To do so, we crossed SORLA WT, SORLA GGA, and
SORLA FTAF lines with the 5xFAD model of AD (Oakley et al.,
2006). As quantified by ELISA, expression of SORLA GGA resulted
in an increase in A40 and A42, but not in soluble APP and
APP (sAPP and sAPP), compared with SORLA WT (Fig.
5A,B). The increase in A40 and A42 levels was specific for the
soluble fraction of the peptides (Fig. 5B) and not seen for the
membrane bound (Fig. 5C) or the formic acid soluble (Fig. 5D)
fractions that represent different forms of A aggregates. In
SORLA FTAF, levels of all APP processing products, including
sAPP and sAPP (Fig. 5E) and A40 and A42 (Fig. 5F), were
elevated. Similar to what had been seen for SORLA GGA, levels of
A40 and A42 were significantly elevated in the soluble (Fig.
5F) but not in the membrane bound (Fig. 5G) or the formic acid
soluble (Fig. 5H) fractions. The observation that the SORLA mu-
tants primarily impact soluble A species is in line with a role for
this receptor in controlling proximal steps in A production and
catabolism. The above data suggested that loss of retromer inter-
action blocked the ability of SORLA to protect APP from proteo-
lytic breakdown while loss of GGA interaction abrogated its
activity to cause lysosomal catabolism of A but did not impact
Figure 6. SORLA FTAFmice have decreased levels of humanAPP.A, Immunoblot analyses for APP and BACE1 in cortical brain extracts showing decreased levels of APP but not BACE1 in SORLA FTAF
mice. Tubulin served as loading control.B, C, Densitometric scanning of replicateWestern blots (as exemplified inA) confirms normal levels of BACE1 (B) but decreased levels of APP (C) in SORLA FTAF
compared with SORLAWT and SORLA GGA animals (n 3/group; one-way ANOVA, Tukey post hoc analysis; ***p 0.001). D, ELISA substantiating decreased levels of APP in cortical extracts
of SORLA FTAF compared with SORLAWT and SORLA GGA animals (n 3/group; one-way ANOVA, Tukey post hoc analysis; ***p 0.001).
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APP processing. In line with these conclusions, levels of full-
length human APP were reduced in SORLA FTAF compared with
SORLA WT and SORLA GGA indicating enhanced proteolytic
breakdown of APP when retrograde sorting was blocked (Fig.
6A,C,D). The expression levels of BACE1 were not impacted by
SORLA FTAF or SORLA GGA (Fig. 6A,B).
The loss of SORLA’s ability to mediate lysosomal catabo-
lism of A, when GGA interaction was blocked, was confirmed
in further cell experiments. Thus we generated SH-SY5Y cell
lines overexpressing human APP 695 and either SORLA WT or
SORLA GGA. Similar to the situation in brain extracts (Fig. 1D)
and primary neurons (Fig. 3C), the levels of SORLA GGA in SH-
SY5Y were significantly increased compared with SORLA WT. In
contrast, APP levels were unchanged, indicating normal rates of
processing (Fig. 7A, inset). To study the intracellular catabolism
of A peptides, both cell lines were treated with the -secretase
inhibitor DAPT to block de novo production of A. Subse-
quently, the turnover of intracellular A40 and A42 was deter-
mined in cell extracts as published previously (Caglayan et al.,
2014). In line with an impaired cellular catabolism, intracellular
levels of A40 and A42 decreased slower in SY5Y-GGA com-
pared with SY5Y-WT cells (Fig. 7A,B). Slower decline of A
levels in SY5Y-GGA cells was not from impaired secretion of the
peptides, as A40 and A42 levels were higher in this cell line
both in the cell lysates and in the cell medium after 3 h of DAPT
treatment (Fig. 7C,D). This finding argued for an impaired intra-
cellular catabolism of nascent A peptides in SY5Y-GGA cells
that resulted in intracellular accumulation and, consequently,
enhanced release of the peptides. To substantiate the involve-
ment of lysosomal pathways in the turnover A in cells express-
Figure 7. Impaired ability of SORLA GGA to mediate lysosomal catabolism of A peptides. A, B, SH-SY5Y cells overexpressing human APP 695 together with SORLAWT or SORLA GGA were treated
with 5 M DAPT. At the indicated time points, the levels of intracellular A40 (A) and A42 (B) were determined by ELISA. Data represent the mean	 SEM of nine replicates expressed as
percentage of time point 0 (set to 100%). Where no error bars are visible, they are smaller than the actual symbol shown. The inset in A documents expression of SORLA and APP in the cell extracts
byWestern blotting. C,D, Levels of A40 (C) and A42 (D) are increased in the cell lysate and the cell media of SORLA GGA comparedwith SORLAWT cells. Cells were treatedwith 5M DAPT for 3 h,
and A levels normalized to levels at time point 0 (n 3 replicates). E, F, SORLAWT cells were treated with 5M DAPT in the absence or presence of 100M leupeptin, 10M pepstatin A, and 50
M chloroquine (DAPT Inhibitor). Levels of A40 (E) and A42 (F ) in the cell lysate were determined after 3 h and normalized to levels at time point 0 (n 6 replicates). Application of the
lysosomal inhibitor cocktail reduced catabolism of A40 and A42 compared with the DAPT only condition. Student’s t test (*p 0.05; **p 0.01; ***p 0.001).
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ing SORLA, we treated SY5Y-WT cells with DAPT in the absence
or presence of chloroquine, leupeptin, and pepstatin A. Com-
bined application of these inhibitors of lysosomal proteolysis in-
creased the intracellular levels of A40 and A42 compared with
SY5Y-WT treated with DAPT only (Fig. 7E,F).
Neuronal levels of SORLA GGA were elevated compared
with SORLA WT and SORLA FTAF (Fig. 1D, 3C), suggesting an
increased half-life of SORLA GGA because of the absence of
lysosomal targeting. This hypothesis was substantiated by
pulse-chase experiments in metabolically labeled SH-SY5Y
cells that documented an increased half-life for SORLA GGA
(t1⁄2  7.17 min) compared with SORLA
WT (t1⁄2  3.97) and
SORLA FTAF (t1⁄2  3.43 min; p  0.05 for SORLA variant,
two-way ANOVA; Fig. 8), and further supported GGA-
mediated anterograde sorting of SORLA (and its cargo A) to
lysosomes.
Discussion
Considerable evidence implicates GGA and retromer in sort-
ing defects in AD. Impaired activity of the adaptors is pro-
posed to cause SORLA missorting and to enhance the
amyloidogenic burden in sporadic AD (Wahle et al., 2006;
Tesco et al., 2007; Muhammad et al., 2008). However, GGA
and retromer also bind other cargo relevant to AD, including
-secretase (He et al., 2005; Wahle et al., 2005) or the related
sorting receptors sortilin (Petersen et al., 1997; Nielsen et al.,
2001) and SORCS1 (Lane et al., 2010), complicating the vali-
dation of this hypothesis. Using tailored mouse models ex-
pressing SORLA variants unable to bind GGA or retromer, we
now document the functional interaction of SORLA with ret-
romer and GGA in neurons in the brain. Levels of expression
of other components of the neuronal sorting machinery or of
alternative adaptor cargo were not impacted in these models.
Our findings not only substantiated the relevance of SORLA
and adaptor interaction in vivo, but also uncovered that an-
terograde and retrograde sorting pathways support discrete
receptor activities relevant to AD.
Retromer emerges as a key player in
sorting of proteins important for neuro-
nal functions (Seaman, 2005; Small and
Gandy, 2006; Muhammad et al., 2008;
Siegenthaler and Rajendran, 2012). Dys-
function of this adaptor complex is seen in
AD and PD (Small et al., 2005; Zavodszky
et al., 2014). Binding of SORLA is medi-
ated by the retromer subunit VPS26
(Fjorback et al., 2012), and disruption of
this interaction causes altered localization
and processing of APP in cells (Schmidt et
al., 2007). Also, inactivation of retromer
subunits in flies or mice increases A lev-
els (Muhammad et al., 2008) whereas
pharmacological stabilization of the adap-
tor complex decreases APP processing
(Mecozzi et al., 2014). In our mouse
model, deletion of the retromer binding
site in SORLA FTAF results in enhanced
proteolytic breakdown of human APP as
judged by the decreased levels of the pre-
cursor (Fig. 6) and a concomitant increase
in all processing products (Fig. 5E,F) in
the 5xFAD line. Accelerated loss of full-
length APP was not obvious for the mu-
rine wild-type protein (Fig. 2A), likely
because this APP species is less prone to amyloidogenic processing than
the human mutant APPSwe(K670N),Florida(I716V),London(V717I) variant ex-
pressed in the 5xFAD line. In primary neurons, SORLAFTAF is depleted
from the TGN but accumulates in early endosomes (Fig. 4D) support-
ing a model in which retrograde sorting results in sequestration of
SORLA and APP in the TGN, protecting APP from processing in the
secretory compartments (amyloidogenic pathway) and at the cell sur-
face (nonamyloidogenic pathway). An increase in all APP processing
products is also seen when the expression of SORLA is moderately re-
Figure 8. Prolonged half-life of SORLA GGA compared with other receptor variants. Pulse-
chase experiments were performed in SH-SY5Y cells stably transfected with SORLAWT,
SORLA GGA, or SORLA FTAF, and the amount of metabolically labeled SORLA at the chase time
points determined by Western blotting (as exemplified in the inset). Following densitometric
scanning of replicate blots, values were normalized to time point 0 of each experiment (set to
100%). A best-fit, one-phase exponential decay curve (y Span*eK*x Plateau) was de-
termined using GraphPad Prism software, with t1⁄2  0.6932/K. Based on the curve fit, the
protein half-life was t1⁄2  3.97 min for SORLA
WT, 3.43 min for SORLA FTAF, but 7.17 min for
SORLA GGA (n 8 replicates per condition). Data represent the mean	 SEM with the best-fit
lines overlaid. Two-way ANOVA analysis (interaction between time and SORLA variant, n.s.,
time, p 0.001, SORLA variant, p 0.05) indicated that the SORLA GGA cohort is significantly
different from the other SORLA constructs.
Figure 9. Model of SORLA trafficking pathways in amyloidogenic processes. GGAs mediate anterograde sorting of SORLA and
impact SORLA-directed A catabolism. An inherited mutation in SORL1 that disrupts A binding, abrogating SORLA-dependent
lysosomal-catabolism of A, is implicated in an autosomal-dominant familial form of AD (FAD). Retromer mediates retrograde
sorting of SORLA, and disrupting this pathway reduces APP levels in the TGN and results in overall enhanced APP processing rate.
Low levels of SORLA or retromer components in the brain are considered risk factors promoting late-onset forms of AD (LOAD).
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ducedbysiRNAto levelsobserved in individualswithSORL1 riskalleles
(Schmidt et al., 2012). Jointly, these observations suggest that altered
APP sorting is a likely cause of AD in sporadic cases associated with risk
alleles encoding SORLA or retromer subunits. A shift of SORLA from
theTGNtoearlyendosomes,andenhancedAPPprocessing, isalsoseen
in mice expressing a SORLA variant lacking an acidic tail motif (Burgert
et al., 2013). This motif serves as a binding site for AP1 and PACS1, two
other adaptors implicated in retrograde sorting. Likely, several adaptor
pathways serve a redundant function in retrograde sorting of SORLA/
APP complexes, and more severe phenotypes may be expected with
receptor variants lacking acidic and FTAF motifs.
Contrary to the situation with SORLA FTAF, loss of interaction
with GGAs results in accumulation of SORLA GGA in the TGN
and in early endosomes. Most likely, internalization of
SORLA GGA molecules from the cell surface provides a sufficient
supply of receptors to endosomal compartments to sustain ret-
rograde sorting of APP (Fig. 4D). In line with this assumption,
overall processing of APP is not increased in the SORLA GGA
mouse (Fig. 5A). BACE, an alternative ligand for GGAs (Wahle et
al., 2005), shows normal expression (Fig. 6A) and activity (Fig.
5A) in SORLA GGA mice. Apparently, this function of GGAs is not
impacted by the SORLA GGA mutation. This led us to hypothesize
that failure of SORLA to interact with GGAs disrupts anterograde
movement of SORLA and A to lysosomes, a route that regulates
intracellular levels of receptor and ligand. Our studies in the hu-
man neuronal cell line SH-SY5Y cells (Fig. 7, 8) confirmed this
hypothesis. We used SH-SY5Y cells in these experiments, as pri-
mary neuronal cultures generated too low a yield to successfully
perform the pulse-chase pull-downs or to measure acute A lev-
els after DAPT treatment. However, our findings in SH-SY5Y
cells are supported by studies in primary neuronal cultures dem-
onstrating reduced SORLA GGA localization in Lamp1-positive
vesicles compared with SORLA WT (Fig. 4C). The ability to direct
A to lysosomes is also blocked in a SORLA mutant identified in
a family with an autosomal-dominant form of AD (Pottier et al.,
2012). This mutation disrupts the binding site for A in the
VPS10P domain of SORLA (Caglayan et al., 2014; Kitago et al.,
2015). Although human mutations in GGA or in the GGA bind-
ing domain of SORL1 have not been reported yet, our findings
suggest that defects in the anterograde sorting pathway for A
may underlie some early onset forms of AD not linked to APP or
presenilin mutations.
In conclusion, our findings established the causal relationship
in a neuronal protein sorting machinery composed of SORLA
and adaptors GGA and retromer, and their relevance for amy-
loidogenic processes in the brain (Fig. 9). Further studies are
likely to define additional regulatory components of this sorting
pathway central to brain (patho)physiology.
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